Plasma and cerebrospinal fluid concentrations treated with daily dose and high dose weekly erlotinib in non-small cell lung cancer patients with central nervous system metastases

Plasma and cerebrospinal fluid concentrations treated with daily dose and high dose weekly erlotinib in non-small cell lung cancer patients with central nervous system metastases - CSF concentrations treated with high dose weekly erlotinib in patients with CNS metastases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004703

Enrollment

Registered

2010-12-10

Start date

2011-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

central nervous system metastases of non-small cell lung cancer with active EGFR mutations treated with daily dosing erlotinib

Interventions

erlotinib: 150mg daily Failure with CNS metastases: 1500 mg weekly erlotinib: 150mg daily PK/PD analyses in day8 and in day15 erlotinib: 1500mg weekly PK/PD analyses in day8

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.non-small cell lung cancer 2.nervous system metastases 3.active EGFR mutations 4.obtained informed consents

Exclusion criteria

Exclusion criteria: 1.IIPs 2.drug hypersensitivity reaction with gefitinib or erlotinib 3.high risk of brain herniation by lumbar puncture 4.unsuitable for treatment

Design outcomes

Primary

Measure	Time frame
relation of clinical efficacy and CSF penetration rate of erlotinib	—

Countries

Japan

Contacts

Public ContactTatsuo Kimura

Osaka City University Department of Respiratory medicine

kimutats@med.osaka-cu.ac.jp06-6645-3916

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026